Uwm Research Foundation, Inc.

Terry S Clayton

James M Cook

Michael Ming-Jin Poe

Ojas A Namjoshi

Hiteshkumar D Jain

Yun Teng Johnson

Jie Yang

Sundari K Rallipalli

Zhi-jian Wang

Described herein are &#x3b1;3 or &#x3b1;2 or &#x3b1;2/&#x3b1;3 GABAergic receptor subtype selective ligands, pharmaceutical compositions, and methods of use of such ligands and compositions in treatment of anxiety disorders, epilepsy and schizophrenia with reduced sedative and ataxic side effects. In embodiments, such as &#x3b1;3 or &#x3b1;2 or &#x3b1;2/&#x3b1;3 GABAergic receptor subtype selective ligands lack ester linkages and may be thus relatively insensitive to hydrolysis by esterases.

GABAergic receptor subtype selective ligands and their uses

Gabaergic receptor subtype selective ligands and their uses

Growing community of inventors

Colorado Springs, CO, United States of America

Terry S Clayton